Related Experiment Videos

Abnormal calcium metabolism in hemodialyzed patients with diabetic nephropathy

Nephron
|January 1, 1984
PubMed

Insights

Patients with diabetes mellitus nephropathy undergoing hemodialysis show fewer bone changes and lower parathyroid hormone levels compared to non-diabetic patients. Higher calcitonin levels were also observed in the diabetic group.

Area of Science:

  • Nephrology
  • Endocrinology
  • Bone Metabolism

Background:

  • Diabetes mellitus nephropathy and chronic glomerulonephritis are leading causes of end-stage renal disease.
  • Altered calcium and bone metabolism are common complications in patients undergoing hemodialysis.
  • Differences in bone disease progression between diabetic and non-diabetic hemodialysis patients are not fully understood.

Purpose of the Study:

  • To compare calcium metabolism and bone changes in hemodialyzed patients with diabetes mellitus nephropathy (HD/DM) versus hemodialyzed non-diabetic patients with chronic glomerulonephritis (HD/non-DM).
  • To investigate the relationship between parathyroid hormone, calcitonin levels, and bone health in these patient groups.

Main Methods:

  • Comparative study of hemodialysis patients.
  • Assessment of bone changes using X-ray analysis of mandibular lamina dura and trabecular patterns.
  • Measurement of serum c-terminal parathyroid hormone and serum calcitonin levels.

Main Results:

  • Hemodialyzed patients with diabetes mellitus nephropathy (HD/DM) exhibited a lower incidence of visible bone changes compared to hemodialyzed non-diabetic patients (HD/non-DM).
  • Serum c-terminal parathyroid hormone levels were significantly lower in the HD/DM group.
  • Serum calcitonin levels were significantly higher in the HD/DM group.

Conclusions:

  • Lower levels of c-terminal parathyroid hormone in HD/DM patients may contribute to the reduced incidence of bone changes.
  • Elevated calcitonin levels in HD/DM patients might play a role in modulating bone metabolism.
  • These findings suggest distinct pathways of bone disease in diabetic versus non-diabetic chronic kidney disease patients on hemodialysis.

Related Concept Videos